
    
      Patients diagnosed with COVID-19 infection by nasopharyngeal viral swab, classified as severe
      disease, category 5, by the WHO Ordinal Scale For Clinical Improvement (who require oxygen
      support by high flow nasal cannula but do not require mechanical ventilation) at the time of
      initiation of therapy will be offered treatment with Opaganib, 500 mg Q12 hours.

      Opaganib will be continuously administered for up to 2 weeks, until discharged on room air
      (if earlier than 2 weeks), upon voluntary withdrawal is initiated by the patient or when the
      physician decides that it is not in the patient's best interest to continue.
    
  